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MDS) and approximately 40% were in ﬁrst complete remis-
sion or ﬁrst chronic phase. 93% of transplantations used
donors younger than 50 (median 35.8, range 18-61). The
majority of patients received myeloablative preparative
regimens (88%) and bone marrow grafts (62%). All patients
received calcineurin inhibitor containing GVHD prophylaxis
and 20% received in vivo T cell depletion. We identiﬁed three
donor characteristics associated with overall survival; donor
age, high resolution donor-recipient HLA-match and ABO
blood group match. Risk adjusted 5-year survival rates were
37%, 33% and 29% with donors aged 18-32, 33-50, and >50
years, respectively (p<0.0001). Corresponding hazard ratios
were 1.13 (p¼0.0004) for donors aged 33e50 years and 1.29
(p<0.001) for donors >50 years compared with donors aged
18 e 32 years. Mortality risks were higher with one (HR 1.24,
P < .0001) and two (HR 1.62, P < .0001) HLA-mismatches
compared with HLA-matched transplants and minor (HR
1.10, P ¼ .002) or major (HR 1.13, P ¼ .001) ABO blood group
mismatch compared with ABO-matched transplants. A sub-
analysis investigated the possibility that the associationwith
donor age may be due to underlying genetic disparity
between donor and recipient. That is, recipients with rare
HLA genotypes tend to have fewer matched donors to choose
from and thus more likely to receive a graft from an older
donor. Recipient genotypes were assigned to quartiles using
frequency data from 4 million NMDP donors as a reference.
The lowest frequency quartile was associated with donors
older than 50 (p<0.0001) and higher rates of HLA mis-
matching (p<0.001) but no association was found between
genotype frequency and overall mortality. Acute GVHD risks
were associated with donor age and HLA match and, donor
parity, the only donor characteristic associated with chronic
GVHD (table). In summary, the data recommend the
consideration of donor age and ABO blood group match to
maximize survival when selecting among comparably HLA-
matched adult unrelated stem cell donors for treatment of
a hematologic malignancy.68
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Background: Umbilical cord blood transplantation (UCBT) is
associated with delay in platelet recovery. However, the
underlying factors inﬂuencing this delayed recovery remain
poorly understood. With the aim of identifying factors that
inﬂuence platelet engraftment, we retrospectively analyzed
data from 68 consecutive myeloablative UCBT recipients
transplanted between April 2006 and March 2012.
Methods: Forty-two (62%) patients received high-dose TBI
(1320 cGy), cyclophosphamide and ﬂudarabine (FLU); while
26 (38%) received Treosulfan, FLU, and a single fraction of
200cGy TBI. Graft-versus-host-disease (GVHD) prophylaxis
consisted of cyclosporine and mycophenolate mofetil.
Platelet recovery was deﬁned as the ﬁrst day of a platelet
count 20 and 50 x 109/L without transfusion for 7 days.
Cumulative incidence (CI) curves were used to estimate the
probabilities of platelet engraftment in the ﬁrst 100 days
post- transplant. A proportional hazards regression model
was used to evaluate the association between CD34+ celldose and platelet engraftment. Factors considered as
potential predictors or confounders included age at trans-
plant, sex, race, body mass index (BMI), disease risk, CMV
seropositivity, presence of minimal residual disease at
transplant (MRD), number of UCB units infused, acute GVHD,
total nucleated cells (TNC) and CD34+ cells.
Results:Median age and BMIwere 36 years (range,1-63) and
26 kg/m2 (range, 16-41), respectively. The majority of
patients (88%) received 2 cord blood units (n¼60). Twenty-
seven (40%) hadMRD and 46 (68%) were CMV seropositive at
time of transplant. Median total infused cell doses were: 3.9
x 107 TNC/kg (range: 2.2-11.2) and 0.25 x 106 CD34+ cells/kg
(range: 0.09 e 1.46). The 100-day CI of platelet engraftment
was 65% (95% CI: 53-76%) for platelets 20 109/L and 59%
(95% CI: 47-71%) for platelets 50 109/L. In univariate anal-
ysis higher CD34+ infused dose was signiﬁcantly associated
with platelet engraftment [HR¼1.4 (95% CI: 1.0-1.9, P ¼ .03)].
Furthermore, platelet engraftment was suggestively slower
among patients with higher BMI [HR¼0.9 (95% CI: 0.9-1.0, P
¼ .06)] while presence of aGVHD grade III-IV was associated
with higher rate of engraftment [HR¼2.1 (95% CI: 0.8-5.9, P¼
.07)]. No signiﬁcant associations were found between all the
others factors analyzed and platelet recovery.In multivari-
able analysis the association between larger CD34+ dose and
higher rate of engraftment remained statistically signiﬁcant
[HR¼1.9 (95% CI: 1.3-2.8, P < .001]. In addition, CMV sero-
positivity [HR¼0.4 (95% CI: .0.2-0.9, P ¼ .02)] became
signiﬁcantly associated with a slower rate of engraftment.
Conclusions: These results indicate that the infused CD34+
dose is a strong independent predictor of platelet engraft-
ment. Furthermore we should expect an earlier sustained
platelet recovery among CMV seronegative patients.IMMUNE RECONSTITUTION ORAL
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Low dose interleukin-2 (IL-2) can increase regulatory T
cells (Treg) and has therapeutic beneﬁt in steroid refractory
cGVHD. To further deﬁne immunological changes underlying
the response to IL-2 and to determine tolerability, we per-
formed phenotypic characterization and functional analysis
of Treg and natural killer (NK) cells in individuals given IL-2.
Six healthy volunteers received subcutaneous ultra low dose
IL-2 (0.2MIU/m2/day) for 5 days without signiﬁcant side
effects. Two patients with steroid and calcineurin-refractory
cGVHD received the same dose of IL-2 daily for 4 or 8 weeks,
after HLA identical myeloablative stem cell transplant (SCT)
for AML. Patient 1 (50 year old male, 3 yr post SCT) had skin
and fascial GVHD affecting the lower limbs. Patient 2 (44 year
old female, 2 yr post SCT) had upper gastrointestinal cGVHD.
Both patients had a prompt and durable partial response by
